阿斯利康公司也寻求在巴西销售那些专利保护即将到期的产品。
AstraZeneca is seeking approval to sell cheap off-patent drugs to Brazil.
阿斯利康公司总裁布伦南曾经做过药品推销员，他也承认制药企业可能在这方面做过头了。
AstraZeneca's boss, Mr Brennan, is a former drugs salesman and he acknowledges that companies may have gone too far.
这类药物包括雅培制药公司的利普安、阿斯利康公司的高舍瑞林和赛诺菲·安万特集团的醋酸亮丙瑞林。
The medications include Abbott Laboratories inc's Lupron, AstraZeneca Plc's Zoladex and Sanofi-Aventis SA's Eligard.
欧洲几大股指全线上扬，此前英国制药企业阿斯利康公司、德国拜尔公司、英国电信公司和法国电信公司纷纷公布利好财报。
European indexes all jumped following strong earnings from pharmaceuticals company AstraZeneca PLC, drug and materials company Bayer AG and telecommunications companies BT PLC and France telecom SA.
阿斯利康公司的Iressa和Amgen公司的Vectibix是目前用于临床治疗结直肠肿瘤、肺癌、乳腺癌和其他肿瘤的EGFR拮抗剂。
Iressa from AstraZeneca and Vectibix from Amgen are among EGFR blockers now available to treat colorectal, lung, breast and other cancers.
在一次采访中，tyrer博士表示，没有理由相信任何其他抗精神病药例如礼来公司奥氮平或阿斯利康公司的思瑞康等用于治疗躁狂将更为有效。
In an interview, Dr. Tyrer said there was no reason to believe that any other antipsychotic drug used for aggression, like Zyprexa from Eli Lilly or Seroquel from AstraZeneca, would be more effective.
阿斯利康（一家英国的大型制药公司）最近宣布作为削减成本的手段之一，它开始将生产转移到亚洲。
AstraZeneca, a big British drugs firm, recently announced that it will start shifting manufacturing operations to Asia as part of a cost-cuttingdrive.
但身为英国大型制药公司阿斯利康的首席执行官，满怀自信的他表明了制药业的远期前景。
But as chief executive of AstraZeneca, a big British drugs firm, his brimming self-confidence is a reminder of the genuine long-term promise of the pharmaceuticals industry.
在其收购的过程中被正处于顶峰时期的职业收购者LordHansan捅了一刀，不怀好意的汉森信托用清盘价竞标，最后导致卜内门公司剥离了它的制药部门，今天的阿斯利康。
Prodded by the threat of a hostile break-up bid from Lord Hanson, a corporate raider at the height of his powers, ICI floated off its drugs division, now AstraZeneca.
阿斯利康并不是唯一一家在新领域应用诱导能干细胞的公司。
And AstraZeneca is not the only company using iPS cells in new ways.
在中国开展药物研究的其他主要制药公司包括诺华，阿斯利康，辉瑞，葛兰素史克和罗氏。
Other major drug companies with a research presence in China include Novartis AG, AstraZeneca Plc, Pfizer inc., GlaxoSmithKline and Roche Holding AG.
我们认为阿斯利康制药公司的董事会目前还没有准备好要进行一场价格合理的交易。
We do not believe that the AstraZeneca board is currently prepared to recommend a deal at a reasonable price.
根据此次提供的分别占45%和55%的现金加股票报价，辉瑞制药公司的股东将会持有合并后公司74%的股份，而阿斯利康制药公司的股东将会持有其余股份。
Based on the cash-and-stock offer, 45% and 55% respectively, Pfizer shareholders would hold 74% of the combined company while AstraZeneca shareholders would hold the remaining equity.
阿斯利康是全球领先的跨国制药企业，位列《财富》杂志全球500强第252位（07年公布最新排名），2006年公司全球营业额高达265亿美元。
AstraZeneca is one of the world's leading pharmaceutical companies with sales reaching $26.5 billion in 2006 and ranks No. 252 on the Fortune 500 list in 2007.
阿斯利康是全球领先的跨国制药企业，位列《财富》杂志全球500强第252位（07年公布最新排名），2006年公司全球营业额高达265亿美元。
AstraZeneca is one of the world's leading pharmaceutical companies with sales reaching $26.5 billion in 2006 and ranks No. 252 on the Fortune 500 list in 2007.
应用推荐